Gemcitabine and Cetuximab for Cholangiocarcinoma Treatment
Author Information
Author(s): Martin F Sprinzl, Carl C Schimanski, Markus Moehler, Simin Schadmand-Fischer, Peter R Galle, Stephan Kanzler
Primary Institution: Johannes-Gutenberg University, Mainz, Germany
Hypothesis
Can gemcitabine combined with cetuximab improve outcomes in patients with unresectable cholangiocarcinoma?
Conclusion
The combination of gemcitabine and cetuximab may improve survival and quality of life in patients with cholangiocarcinoma.
Supporting Evidence
- The patient showed a partial response with over 30% reduction in tumor size after treatment.
- Ca 19-9 serum levels returned to normal after 16 weeks of treatment.
- The patient's performance status stabilized during the treatment.
Takeaway
A 69-year-old man with a type of cancer called cholangiocarcinoma was treated with two medicines, and it helped him feel better and live longer.
Methodology
The patient received gemcitabine and cetuximab as palliative chemotherapy over 20 cycles.
Limitations
The study is based on a single case, limiting the generalizability of the findings.
Participant Demographics
69-year-old male with non-resectable cholangiocarcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website